Optically measured microvascular blood flow contrast of malignant breast tumors.
Microvascular blood flow contrast is an important hemodynamic and metabolic parameter with potential to enhance in vivo breast cancer detection and therapy monitoring. Here we report on non-invasive line-scan measurements of malignant breast tumors with a hand-held optical probe in the remission geo...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4072684?pdf=render |
| _version_ | 1828387810171682816 |
|---|---|
| author | Regine Choe Mary E Putt Peter M Carlile Turgut Durduran Joseph M Giammarco David R Busch Ki Won Jung Brian J Czerniecki Julia Tchou Michael D Feldman Carolyn Mies Mark A Rosen Mitchell D Schnall Angela DeMichele Arjun G Yodh |
| author_facet | Regine Choe Mary E Putt Peter M Carlile Turgut Durduran Joseph M Giammarco David R Busch Ki Won Jung Brian J Czerniecki Julia Tchou Michael D Feldman Carolyn Mies Mark A Rosen Mitchell D Schnall Angela DeMichele Arjun G Yodh |
| author_sort | Regine Choe |
| collection | DOAJ |
| description | Microvascular blood flow contrast is an important hemodynamic and metabolic parameter with potential to enhance in vivo breast cancer detection and therapy monitoring. Here we report on non-invasive line-scan measurements of malignant breast tumors with a hand-held optical probe in the remission geometry. The probe employs diffuse correlation spectroscopy (DCS), a near-infrared optical method that quantifies deep tissue microvascular blood flow. Tumor-to-normal perfusion ratios are derived from thirty-two human subjects. Mean (95% confidence interval) tumor-to-normal ratio using surrounding normal tissue was 2.25 (1.92-2.63); tumor-to-normal ratio using normal tissues at the corresponding tumor location in the contralateral breast was 2.27 (1.94-2.66), and using normal tissue in the contralateral breast was 2.27 (1.90-2.70). Thus, the mean tumor-to-normal ratios were significantly different from unity irrespective of the normal tissue chosen, implying that tumors have significantly higher blood flow than normal tissues. Therefore, the study demonstrates existence of breast cancer contrast in blood flow measured by DCS. The new, optically accessible cancer contrast holds potential for cancer detection and therapy monitoring applications, and it is likely to be especially useful when combined with diffuse optical spectroscopy/tomography. |
| first_indexed | 2024-12-10T06:01:25Z |
| format | Article |
| id | doaj.art-29acb8a05d70406fa62d214c902159db |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T06:01:25Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-29acb8a05d70406fa62d214c902159db2022-12-22T01:59:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e9968310.1371/journal.pone.0099683Optically measured microvascular blood flow contrast of malignant breast tumors.Regine ChoeMary E PuttPeter M CarlileTurgut DurduranJoseph M GiammarcoDavid R BuschKi Won JungBrian J CzernieckiJulia TchouMichael D FeldmanCarolyn MiesMark A RosenMitchell D SchnallAngela DeMicheleArjun G YodhMicrovascular blood flow contrast is an important hemodynamic and metabolic parameter with potential to enhance in vivo breast cancer detection and therapy monitoring. Here we report on non-invasive line-scan measurements of malignant breast tumors with a hand-held optical probe in the remission geometry. The probe employs diffuse correlation spectroscopy (DCS), a near-infrared optical method that quantifies deep tissue microvascular blood flow. Tumor-to-normal perfusion ratios are derived from thirty-two human subjects. Mean (95% confidence interval) tumor-to-normal ratio using surrounding normal tissue was 2.25 (1.92-2.63); tumor-to-normal ratio using normal tissues at the corresponding tumor location in the contralateral breast was 2.27 (1.94-2.66), and using normal tissue in the contralateral breast was 2.27 (1.90-2.70). Thus, the mean tumor-to-normal ratios were significantly different from unity irrespective of the normal tissue chosen, implying that tumors have significantly higher blood flow than normal tissues. Therefore, the study demonstrates existence of breast cancer contrast in blood flow measured by DCS. The new, optically accessible cancer contrast holds potential for cancer detection and therapy monitoring applications, and it is likely to be especially useful when combined with diffuse optical spectroscopy/tomography.http://europepmc.org/articles/PMC4072684?pdf=render |
| spellingShingle | Regine Choe Mary E Putt Peter M Carlile Turgut Durduran Joseph M Giammarco David R Busch Ki Won Jung Brian J Czerniecki Julia Tchou Michael D Feldman Carolyn Mies Mark A Rosen Mitchell D Schnall Angela DeMichele Arjun G Yodh Optically measured microvascular blood flow contrast of malignant breast tumors. PLoS ONE |
| title | Optically measured microvascular blood flow contrast of malignant breast tumors. |
| title_full | Optically measured microvascular blood flow contrast of malignant breast tumors. |
| title_fullStr | Optically measured microvascular blood flow contrast of malignant breast tumors. |
| title_full_unstemmed | Optically measured microvascular blood flow contrast of malignant breast tumors. |
| title_short | Optically measured microvascular blood flow contrast of malignant breast tumors. |
| title_sort | optically measured microvascular blood flow contrast of malignant breast tumors |
| url | http://europepmc.org/articles/PMC4072684?pdf=render |
| work_keys_str_mv | AT reginechoe opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT maryeputt opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT petermcarlile opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT turgutdurduran opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT josephmgiammarco opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT davidrbusch opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT kiwonjung opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT brianjczerniecki opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT juliatchou opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT michaeldfeldman opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT carolynmies opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT markarosen opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT mitchelldschnall opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT angelademichele opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors AT arjungyodh opticallymeasuredmicrovascularbloodflowcontrastofmalignantbreasttumors |